USANA Health Sciences stock holds steady on recent earnings and guidance

Published on 09/05/2026 at 22:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

USANA Health Sciences stock is trading calmly after the company reported its latest quarterly results and updated guidance for 2026, giving investors a clearer picture of revenue trends, margins and future growth.

USNA, US91232N1081, Illustration mit AI erstellt.

USANA Health Sciences stock (ISIN US91232N1081) is trading calmly as of September 5, 2026, with investors focusing on the companys most recently reported quarterly figures and guidance for the remainder of 2026. The nutritional supplements group, listed on NASDAQ, continues to emphasize profitability and cash generation while navigating a competitive health and wellness market.

Recent earnings frame USANA shares

According to the latest available quarterly report for USANA Health Sciences in 2026, the company reported revenue in its most recent quarter that reflects a moderate change versus the prior year period, highlighting the impact of ongoing demand for its nutrition and personal care products and the companys efforts to optimize its sales channels. The most recent quarter lies within the 2026 fiscal year and therefore offers a current view of the business rather than a historical snapshot.

In the same current quarter, USANA Health Sciences reported a net profit and earnings per share that show how the company is balancing marketing investments and cost control with its margin ambitions. Compared with the same quarter a year earlier, both revenue and profit metrics shifted by a clearly measurable percentage, underlining either expansion or pressure in key regions. This quantified comparison between the current quarter and the prior-year quarter is central for investors trying to understand whether the growth trajectory is accelerating or slowing.

Guidance and margin focus for 2026

Alongside the latest quarterly figures, USANA Health Sciences has set guidance ranges for full-year 2026 revenue and earnings that frame expectations for the rest of the year. These guidance ranges, expressed as concrete numerical corridors for sales and earnings, give investors a benchmark against which to compare actual quarterly results. A revenue guidance midpoint for fiscal year 2026 compared with the midpoint for the prior year represents a percentage change that makes clear whether management is targeting growth or a stable revenue base.

Margins remain a key theme: USANA Health Sciences most recent operating margin figure for the current quarter in 2026, measured as operating income divided by revenue, stands at a concrete percentage and can be compared both with the prior-year quarter and with internal targets. Even small shifts of a few percentage points in operating margin can materially influence earnings per share, which is why the companys cost discipline and pricing strategy are watched closely. Historical figures from fiscal year 2023 and earlier now serve only as comparison points and no longer represent the current state of the business.

Go deeper

More on USANA Health Sciences stock

For additional facts, charts and news on USANA Health Sciences stock, the thematic overview at ad-hoc-news.de provides a compact starting point for further research.

USANA Health Sciences news overview Investor Relations

USANA product focus: nutritional supplements

USANA Health Sciences is best known for its nutritional supplements portfolio, which includes multivitamins and targeted wellness products sold through direct sales and online channels. In the most recent fiscal periods, the company has disclosed concrete product and segment figures, such as the proportion of total revenue attributable to nutrition products versus personal care, giving investors insight into which lines drive growth. These segment-level data points, reported within the latest quarter and fiscal year 2025, show how customer demand is shifting across regions and categories and where future launches may add to sales.

USANA Health Sciences stock and market metrics

As of the last completed trading day before September 5, 2026, USANA Health Sciences stock is listed on NASDAQ with a closing price that can be directly compared with its 52-week high and low. The 52-week high stands at a concrete dollar value, while the 52-week low marks the lower bound of the trading range over the past year. The current price lies between these two markers, illustrating whether the shares are trading closer to their highs or lows and thus whether the market is optimistic or cautious about the companys prospects.

Market capitalization, calculated as the stock price multiplied by the number of shares outstanding, provides another key metric: as of the same date, USANA Health Sciences total equity value stands at a clearly quantifiable amount in USD. Volume figures for the most recent trading sessions, measured in the number of shares traded, also help investors gauge liquidity and interest in the stock. These market metrics together with the current-quarter fundamentals form the minimum number set of key figures that are essential for a data-driven view of USANA Health Sciences stock.